• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by PolarityTE Inc. (Amendment)

    2/14/23 11:11:43 AM ET
    $PTE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PTE alert in real time by email
    SC 13G/A 1 ea173556-13ga1honig_polarity.htm AMENDMENT NO. 1 TO SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G/A

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (AMENDMENT NO. 1)

     

    POLARITYTE, INC.

     

    (Name of Issuer)

     

    COMMON STOCK, PAR VALUE $0.001 PER SHARE

     

    (Title of Class of Securities)

     

    731094108

     

    (CUSIP Number)

     

    December 31, 2022

     

    (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☒Rule 13d-1(c)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    (Continued on following page(s)

     

    Page 1 of 6 Pages

     

     

     

     

     

     

    CUSIP No. 731094108   13G/A   Page 2 of 6 Pages

     

    1. NAMES OF REPORTING PERSON
      S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
       
      Four Kids Investment Fund LLC
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:
      (a)   ☐
      (b)   ☐
    3.   SEC USE ONLY
       
    4.   CITIZENSHIP OR PLACE OF ORGANIZATION
      Florida
    5. SOLE VOTING POWER, NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON – None
       
    6. SHARED VOTING POWER – 0 Shares
       
    7. SOLE DISPOSITIVE POWER – None
       
    8. SHARED DISPOSITIVE POWER – 0 Shares
       
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON – 0 Shares
     
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐
       
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
     

    None

    12. TYPE OF REPORTING PERSON
      CO

     

     

     

     

    CUSIP No. 731094108   13G/A   Page 3 of 6 Pages

     

    1. NAMES OF REPORTING PERSON
      S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
       
      Jonathan Honig
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:
      (a)   ☐
      (b)   ☐
    3.   SEC USE ONLY
       
    4.   CITIZENSHIP OR PLACE OF ORGANIZATION
      United States
    5. SOLE VOTING POWER, NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON – None
       
    6. SHARED VOTING POWER – 0 Shares
       
    7. SOLE DISPOSITIVE POWER – None
       
    8. SHARED DISPOSITIVE POWER – 0 Shares
       
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON – 0 Shares
     
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐
       
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
     

    None

    12. TYPE OF REPORTING PERSON
      IN

     

     

     

     

    CUSIP No. 731094108   13G/A   Page 4 of 6 Pages

     

    ITEM 1 (a) NAME OF ISSUER:

     

    PolarityTE, Inc., a Delaware corporation

     

    ITEM 1 (b) ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:

     

    123 Wright Brothers Drive, Salt Lake City, Utah 84116

     

    ITEM 2 (a) NAME OF PERSON FILING:

     

    The statement is filed on behalf of Four Kids Investment Fund LLC and Jonathan Honig (collectively, the “Reporting Persons”). Jonathan Honig is the sole manager of Four Kids Investment Fund LLC and in such capacity has voting and dispositive power over the securities held by such entity and may be deemed, directly or indirectly, to have beneficial ownership of all such shares of common stock.

     

    ITEM 2 (b) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

     

    5825 Windsor Court, Boca Raton, FL 33496

     

    ITEM 2 (c) CITIZENSHIP:

     

    Four Kids Investment Fund LLC is organized in the State of Florida and Jonathan Honig is a citizen of the United States.

     

    ITEM 2 (d) TITLE OF CLASS OF SECURITIES:

     

    Common Stock, par value $0.001 per share

     

    ITEM 2 (e) CUSIP NUMBER:

     

    731094108

     

    ITEM 3 IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B) OR 13D-2(B):

     

    Not applicable

     

    ITEM 4 OWNERSHIP

     

    The information required by Items 4(a) – (c) is set forth in rows (5) – (11) of the cover page for each of the Reporting Persons hereto, including footnotes, and is incorporated herein by reference for the Reporting Persons. The information set forth in Rows (5) – (11) of the cover page for each of the Reporting Persons hereto is made as of December 31, 2022.

     

    ITEM 5 OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

     

    Each of the Reporting Person no longer owns any shares in the Issuer.

     

     

     

     

    CUSIP No. 731094108   13G/A   Page 5 of 6 Pages

     

    ITEM 6 OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

     

    Not applicable

     

    ITEM 7 IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

     

    Not applicable

     

    ITEM 8 IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF A GROUP

     

    Not applicable

     

    ITEM 9 NOTICE OF DISSOLUTION OF GROUP

     

    Not applicable

     

     

     

     

    CUSIP No. 731094108   13G/A   Page 6 of 6 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      February 14, 2023
      (Date)
       
      /s/ Jonathan Honig
      (Signature)
       
      Jonathan Honig
      Sole Manager of Four Kids Investments Fund LLC
      (Name/Title)
       
      /s/ Jonathan Honig
      (Signature)
       
      Jonathan Honig, Individually
      (Name/Title)

     

     

     

     

     

    Get the next $PTE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PTE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PTE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PolarityTE Announces Entry Into a Letter of Intent For Acquisition of the Company

      SALT LAKE CITY, Dec. 27, 2022 /PRNewswire/ --  PolarityTE, Inc. (NASDAQ:PTE), a biotechnology company developing regenerative tissue products and biomaterials (the "Company"), today announced that it signed a non-binding letter of intent (the "LOI") with Michael Brauser ("Brauser") for him to make an offer to acquire 100% of the outstanding equity interests of the Company at a proposed offering price of $1.03 per common share, which would be paid entirely in cash. As of December 23, 2022, there were 7,256,786 shares of the Company's common stock outstanding and unvested restricted stock units covering an additional 256,457 common shares. 

      12/27/22 8:30:00 AM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PolarityTE Reports Third Quarter 2022 Financial Results and Provides Business Update

      SALT LAKE CITY, Nov. 10, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the quarterly period ended September 30, 2022. Recent Business and Financial UpdatesAt the end of April 2022, PolarityTE began enrollment in its Phase III randomized controlled trial (RCT), which is a pivotal study under its open IND for SkinTE®. The Company estimates that it may be able to complete enrollment of 100 subjects sometime in the first six mon

      11/10/22 4:30:00 PM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PolarityTE Confirms Receipt of Unsolicited, Non-Binding Offer to Acquire the Company

      SALT LAKE CITY, Nov. 9, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE), a biotechnology company developing regenerative tissue products and biomaterials, today confirmed that on November 1, 2022, it received an unsolicited, non-binding offer (followed by an amended offer on November 8, 2022) from Michael Brauser to acquire all of the outstanding common stock of the Company not owned by him for $1.25 per share in cash. The offer is subject to various contingencies, including, among others, (1) settlement with warrant holders and satisfactory negotiations with insiders with change of control agreements, (2) minimum tender conditions, (3) a sixty-day due diligence period, and (4) satisfacti

      11/9/22 8:00:00 AM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PTE
    Leadership Updates

    Live Leadership Updates

    See more
    • PolarityTE Announces Resignation of Jeff Dyer from its Board of Directors

      SALT LAKE CITY, Sept. 8, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) a biotechnology company developing regenerative tissue products and biomaterials, today announced that Jeff Dyer, PhD, has decided to resign from its Board of Directors, effective immediately. "On behalf of our Board and PolarityTE's management team, we thank Jeff for his service and longstanding commitment to the Company," stated Richard Hague, Chief Executive Officer of PolarityTE.  "We greatly appreciate the leadership and insight that Jeff has provided over the past five and a half years as we purs

      9/8/22 8:30:00 AM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ambrx Appoints Audit Executive Chris Nolet to Board of Directors

      SAN DIEGO--(BUSINESS WIRE)--​Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code to create Engineered Precision Biologics, today announced the appointment of Chris Nolet to the company’s Board of Directors. Mr. Nolet brings extensive experience as a long-time audit partner and business advisor in the life sciences industry, and has assumed the role of Chair of Ambrx’s Audit Committee. “We are delighted that Chris will be joining our Board of Directors given his deep expertise, knowledge base and industry network,” said Feng Tian, Ph.D., President and CEO of Ambrx. “His experience in helping transition clinical stage companies into commercially integra

      2/23/21 4:05:00 PM ET
      $VIE
      $PTE
      $RVNC
      Major Pharmaceuticals
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Biotechnology: Pharmaceutical Preparations

    $PTE
    Financials

    Live finance-specific insights

    See more
    • PolarityTE Reports Second Quarter 2022 Financial Results and Provides Business Update

      PolarityTE to host conference call and webcast today, August 11, 2022, at 4:30 p.m. ET SALT LAKE CITY, Aug. 11, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the quarterly period ended June 30, 2022. Recent Business and Financial UpdatesIn January 2022, PolarityTE was advised by the U.S. Food and Drug Administration (FDA) that it could conduct human clinical trials under PolarityTE's investigational new drug application (IND

      8/11/22 4:05:00 PM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PolarityTE to Report Q2 2022 Financial Results on August 11, 2022

      SALT LAKE CITY, Aug. 1, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) today announced that it will report results for the quarter ended June 30, 2022, by press release on Thursday, August 11, 2022, at approximately 4:05 p.m. Eastern Time. In addition, the Company will host a conference call and webcast with Q&A on August 11, 2022, at 4:30 p.m. Eastern Time. The conference call can be accessed by calling 1-800-207-0148 with passcode 893469 and referencing "PolarityTE Second Quarter 2022 Business Update and Financial Results." A webcast of the conference call can be accesse

      8/1/22 8:00:00 AM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Polarity TE spins off IBEX Preclinical Research contract research organization

      Dr. Josh Packer acquires IBEX and becomes CEO; maintains existing surgical research team LOGAN, Utah, May 26, 2022 /PRNewswire-PRWeb/ -- IBEX Preclinical Research, Inc., a trusted outsourcing partner and provider of preclinical surgical and toxicological studies in a variety of laboratory animal species, announced that it has been acquired by Josh Packer, DVM. IBEX provides in-vivo research services ranging from relatively simple single-dose pharmacokinetic studies to more complex projects requiring surgical instrumentation. Conducting both GLP and non-GLP non-clinical testing, IBEX supports life science, medical device companies and researchers that specialize in orthopedics, neurosurgical,

      5/26/22 11:15:00 AM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PTE
    SEC Filings

    See more

    $PTE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PolarityTE Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - POLARITYTE, INC. (0001076682) (Filer)

      8/18/23 4:54:40 PM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form NT 10-Q filed by PolarityTE Inc.

      NT 10-Q - POLARITYTE, INC. (0001076682) (Filer)

      8/15/23 4:40:32 PM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PolarityTE Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits

      8-K - POLARITYTE, INC. (0001076682) (Filer)

      8/15/23 4:30:36 PM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Dyer Jeffrey Hansen was granted 42,986 shares, increasing direct ownership by 3,177% to 44,339 units

      4 - POLARITYTE, INC. (0001076682) (Issuer)

      1/30/23 4:30:42 PM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3: New insider Dyer Jeffrey Hansen claimed ownership of 1,353 shares

      3 - POLARITYTE, INC. (0001076682) (Issuer)

      1/30/23 4:15:33 PM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Nolet Chris decreased direct ownership by 72% to 14,403 units

      4 - POLARITYTE, INC. (0001076682) (Issuer)

      1/17/23 4:30:29 PM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PTE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by PolarityTE Inc. (Amendment)

      SC 13G/A - POLARITYTE, INC. (0001076682) (Subject)

      2/14/23 11:11:43 AM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by PolarityTE Inc.

      SC 13G - POLARITYTE, INC. (0001076682) (Subject)

      8/23/22 11:30:24 AM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed

      SC 13G - POLARITYTE, INC. (0001076682) (Subject)

      2/16/21 5:19:31 PM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care